Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 28, 2014; 20(44): 16409-16417
Published online Nov 28, 2014. doi: 10.3748/wjg.v20.i44.16409
Published online Nov 28, 2014. doi: 10.3748/wjg.v20.i44.16409
Management of recurrent hepatitis C virus after liver transplantation
Miguel Jiménez-Pérez, Rocío González-Grande, Liver transplantation and hepatology unit, UGC de Aparato Digestivo Hospital Regional Universitario, 29010 Málaga, Spain
Francisco Javier Rando-Muñoz, Department of Abdominal Diseases, Hospital Nij Smellinghe Ziekenhuis, 9202 NN Drachten, The Netherlands
Author contributions: Jiménez-Pérez M, González-Grande R and Rando-Muñoz FJ contributed equally to this work.
Correspondence to: Miguel Jiménez-Pérez, MD, Liver transplantation and hepatology unit, UGC de Aparato Digestivo, Unidad de Hepatología-Trasplante Hepático, Hospital Regional Universitario de Málaga, Avda Carlos Haya, 29010 Malaga, Spain. miguel.jimenez.sspa@juntadeandalucia.es
Telephone: +34-61-095935 Fax: +34-951-291941
Received: May 14, 2014
Revised: August 27, 2014
Accepted: October 14, 2014
Published online: November 28, 2014
Revised: August 27, 2014
Accepted: October 14, 2014
Published online: November 28, 2014
Core Tip
Core tip: Chronic hepatitis C virus (HCV) infection is the reason for about 50% of liver transplants in the western world. Reinfection of the graft is universal and can compromise graft function and patient survival. The development of an efficient antiviral therapeutic strategy has been the focus of clinical research in recent years, including when, how much and at what point this treatment should be applied. The introduction of new drugs for the treatment of chronic HCV hepatitis may involve therapeutic changes and, perhaps, a better prognosis for these patients, particularly those with severe recurrence or factors predicting rapid progression of fibrosis.